Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


New HIV Treatment
Dec 7, 2002

What does it mean now for new potential therapies now that Gilead Scienes is purchasing Triangle Pharmaceuticals? Are there going to be more options for HIV treatment?

Response from Dr. Wohl

Well, this long anticipated acquisition by Gilead, the maker of tenofovir, of Triangle, a smaller company that produces FTC (a 3TC like drug), will almost certainly result in the development of a co-formulation of tenofovir and FTC. This would be a once daily pill containing these 2 medications and would be a clear alternative to Combivir (AZT + 3TC).

In addition, both companies have an interest in hepatits B therapies (tenofovir and FTC are active against hep B).

I think this is a positive move and look forward to seeing what Gilead will do. DW



Previous
Recent HIV +
Next
Responding to Dr. Wohl

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement